Nivolumab Plus Ipilimumab Prolongs Survival in Treatment-Naïve Advanced Sarcomatoid RCC
November 5th 2022Post hoc CheckMate 214 results show that nivolumab plus ipilimumab extend progression and overall survival in patient with advanced sarcomatoid renal cell carcinoma who have not be previously treated.
Talquetamab/Daratumumab Combination Appears Safe in Patients With Anti-CD38–Refractory Myeloma
August 18th 2022The combination of talquetamab and daratumumab has the potential to demonstrate synergistic clinical activity, and preclinical studies have shown that the addition of daratumumab enhanced talquetamabmediated lysis of multiple myeloma cells.
FOLFOXIRI Plus Bevacizumab Shows Positive Efficacy But Increased Toxicity in CRC Liver Metastases
June 7th 2022Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.
Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma After RVd Treatment
June 5th 2022At the 2022 ASCO Annual Meeting findings from the phase, 3 DETERMINATION trial showed off the survival benefit when adding autologous stem cell transplant and lenalidomide maintenance after RVd treatment for patients with newly diagnosed multiple myeloma.
Six-Year Survival Extends With Brentuximab Vedotin Plus Chemotherapy in Hodgkin Lymphoma
June 4th 2022Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
Prolonged, Deeper Molecular Responses Produced by Asciminib in Chronic-Phase CML
December 12th 2021Findings from the phase 3 ASCEMBL trial showed a consistent improvement in major molecular response rate and depth of response without any new or worsening adverse effects when treating with asciminib versus bosutinib in patients with chronic-phase chronic myeloid leukemia.
Multigene Sequencing Used to Choose Matched Targeted Therapy in mBC Show PFS Improvement
December 7th 2021A pooled analysis of results from the randomized phase 2 SAFIR02_BREAST and SAFIR-PI3K trials show promise for the use of multigene sequencing to select targeted therapy for metastatic breast cancer.